AbbVie joins peers in Middle East with Saudi Arabia plans

AbbVie ($ABBV) is joining the rush to the Middle East with operations in Saudi Arabia. Its deal for the Arab Company for Pharmaceutical Products (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics. AbbVie joins Pfizer ($PFE), which is building a plant there, while Sanofi ($SNY), Merck & Co. ($MRK) and others are establishing production and distribution operations throughout the Middle East. It is a region that is seen as one the emerging markets with the most potential. Story | More

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.